Monte Rosa Therapeutics (NASDAQ: GLUE) stock: the official figures
Monte Rosa Therapeutics (Monte Rosa Therapeutics, Inc.) is listed on Nasdaq under the ticker GLUE and belongs to the health care sector. In fiscal 2025 it reported revenue of $123.7m and a net loss of $38.6m, according to the annual accounts it filed with the regulator.
Identifiers for Monte Rosa Therapeutics: SEC CIK 1826457.
Fiscal 2025 figures
| Item | 2025 | 2024 | Change |
|---|---|---|---|
| Revenue | $123.7m | $75.6m | +63.5% |
| Operating profit | −$54.2m | −$81.1m | — |
| Net profit | −$38.6m | −$72.7m | — |
| Operating margin | −43.8% | −107.3% | +63.4 pts |
| Net margin | −31.2% | −96.1% | +64.9 pts |
| Total assets | $448.7m | $438.7m | +2.3% |
| Equity | $233.1m | $222.9m | +4.5% |
| Cash | $129.9m | $224.3m | −42.1% |
| Operating cash flow | −$22.8m | $42.0m | −154.3% |
Margins are calculated from the filed figures: operating profit and net profit over revenue.
6 fiscal years
| Fiscal year | Revenue | Operating profit | Net profit | Document |
|---|---|---|---|---|
| 2025 | $123.7m | −$54.2m | −$38.6m | Annual report |
| 2024 | $75.6m | −$81.1m | −$72.7m | Annual report |
| 2023 | $0.0m | −$143.3m | −$135.4m | Annual report |
| 2022 | — | −$112.4m | −$108.5m | Annual report |
| 2021 | — | −$72.9m | −$74.0m | Annual report |
| 2020 | — | −$28.0m | −$35.9m | Annual report |
The full income statement, balance sheet and cash flow statement are in the annual accounts of Monte Rosa Therapeutics. Purchases and sales by its executives and directors are in insider transactions.
Frequently asked questions about Monte Rosa Therapeutics
- How much did Monte Rosa Therapeutics earn in fiscal 2025?
- Monte Rosa Therapeutics reported a net loss of $38.6m for fiscal 2025, on revenue of $123.7m. The year before it reported a net loss of $72.7m.
- Where is Monte Rosa Therapeutics listed?
- Monte Rosa Therapeutics is listed on Nasdaq under the ticker GLUE and belongs to the health care sector.
- Where do the figures for Monte Rosa Therapeutics come from?
- From the annual report (Form 10-K) that Monte Rosa Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
The annual accounts come from the annual report (Form 10-K) that Monte Rosa Therapeutics files with the SEC, the US securities regulator. Each fiscal year in the table links to its filing. Celsmar reads the tagged figures from the document and does not adjust them: if an item is not in the filing, it is not shown. More detail in data sources and, if you spot an error, in corrections. What Celsmar is and what it costs, in its fact sheet.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.